Identification of EGFR, MMP9, and AGTR1 as actionable therapeutic targets in acetyl tributyl citrate-driven breast cancer: integrated network toxicology and in vitro validation

Submitted by Anonymous on

BackgroundGrowing exposure to acetyl tributyl citrate (ATBC) drives breast cancer (BC) progression and poses significant challenges to clinical management. H Abstract Background: Growing exposure to acetyl tributyl citrate (ATBC) drives breast cancer (BC) progression and poses significant challenges to clinical...

Cooperation of luteinizing hormone and estradiol in the promotion of goat oocyte maturation via regulation and activation of the GPR30 and EGFR signaling pathways

Submitted by Anonymous on

Abstract The luteinizing hormone (LH) is well established to trigger oocyte maturation and cumulus expansion in preovulatory follicles, primarily through activating the epidermal growth factor (EGF) signaling network. While previous studies have demonstrated that activation of the G protein-coupled estrogen...

CStone Pharmaceuticals-B (02616): IND application for CS5007 (EGFR/HER3 bispecific ADC) approved by China's NMPA

Submitted by Anonymous on

CStonePharmaceuticals-B (02616) announced that the Investigational New Drug (IND) application for CS5007, one of the core candidate drugs in its Pipeline 2.0 portfolio-an EGFR/HER3 bispecific antibody-drug conjugate (ADC)-has been rapidly approved through the National Medical Products Administration (NMPA)’s review and...

TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

Submitted by Anonymous on

Professor Shun Lu, Director of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong Tong University School of Medicine and principal investigator of the trial, said:" These exciting results from SAFFRON represent a critical advance for patients with EGFR- mutated...

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

Submitted by Anonymous on

--BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration has granted Fast Track designation to...

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

Submitted by Anonymous on

--HUTCHMED Limited today announces that positive high-level results from the SAFFRON Phase III trial showed ORPATHYS ® plus TAGRISSO ® demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival versus doublet platinum-based chemotherapy in...

Comparison of healthcare utilization between patients with stage 3–5 CKD and patients with normal-eGFR: an observational study of west region of France

Submitted by Anonymous on

This study aims to compare healthcare utilization between patients with stage 3–5 chronic kidney disease (CKD) and patients with normal estimated glomerular filtration rate (n-eGFR) to identify differences in healthcare needs. This retrospective observational study included patients hospitalized in Western...

Subscribe to Newsfeed